Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients

Laura S. Mertens,Francesco Claps, Roman Mayr,Peter J. Bostrom, Shahrokh F. Shariat,Ellen C. Zwarthoff,Joost L. Boormans,Cheno Abas, Geert J.L.H. van Leenders,Stefanie Götz, Katrin Hippe,Simone Bertz, Yann Neuzillet,Joyce Sanders, Annegien Broeks,Dennis Peters, Michiel S. van der Heijden,Michael A.S. Jewett, Robert Stöhr,Alexandre R. Zlotta

Urologic Oncology: Seminars and Original Investigations(2022)

引用 24|浏览24
暂无评分
摘要
Objectives To determine the association between the FGFR3 mutation status and immuno-histochemistry (IHC) markers (p53 and Ki-67) in invasive bladder cancer (BC), and to analyze their prognostic value in a multicenter, multi-laboratory radical cystectomy (RC) cohort. Patients and methods We included 1058 cN0M0, chemotherapy-naive BC patients who underwent RC with pelvic lymph-node dissection at 8 hospitals. The specimens were reviewed by uro-pathologists. Mutations in the FGFR3 gene were examined using PCR-SNaPshot; p53 and Ki-67 expression were determined by standard IHC. FGFR3 mutation status as well as p53 (cut-off>10%) and Ki-67 (cut-off>20%) expression were correlated to clinicopathological parameters and disease specific survival (DSS). Results pT-stage was 更多
查看译文
关键词
Bladder,Cancer,Urothelial carcinoma,Cystectomy,FGFR3,Mutation,Immunohistochemistry,p53,Ki-67
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要